CHRS Coherus BioSciences PE ratio, current and historical analysis
As of Apr 4, 2025, the CHRS stock has a P/E ratio of 3.13. The calculation is based on the latest EPS of $0.25 and the stock price of $0.78 per share.
CHRS PE ratio history
The mean historical PE ratio of Coherus BioSciences over the last six years is 8.62. The current 3.13 price-to-earnings ratio is 64% less than the historical average. Analyzing the last six years, CHRS's PE ratio reached its highest point in the Dec 2019 quarter at 13.96, with a price of $18.01 and an EPS of $1.29. The Dec 2024 quarter saw the lowest point at 5.52, with a price of $1.38 and an EPS of $0.25.
Coherus BioSciences PE ratio by year
Maximum annual decrease: -32.74% in 2020
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 5.52 | N/A | $1.38 | $0.25 |
| 2023 | N/A | N/A | $3.33 | -$2.53 |
| 2022 | N/A | N/A | $7.92 | -$3.76 |
| 2021 | N/A | N/A | $15.96 | -$3.81 |
| 2020 | 9.39 | -32.74% | $17.38 | $1.85 |
| 2019 | 13.96 | N/A | $18.01 | $1.29 |
| 2018 | N/A | N/A | $9.05 | -$3.22 |
| 2017 | N/A | N/A | $8.8 | -$4.48 |
| 2016 | N/A | N/A | $28.15 | -$3.04 |
| 2015 | N/A | N/A | $22.96 | -$6.01 |
| 2014 | N/A | N/A | $16.32 | -$10.64 |
| 2013 | N/A | N/A | N/A | -$16.1 |
| 2012 | N/A | N/A | N/A | -$15.85 |
Coherus BioSciences PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 5.52 | N/A | $1.38 | $0.25 |
| Sep 2024 | N/A | N/A | $1.04 | -$0.03 |
| Jun 2024 | N/A | N/A | $1.73 | -$0.35 |
| Mar 2024 | N/A | N/A | $2.39 | -$0.73 |
| Dec 2023 | N/A | N/A | $3.33 | -$2.53 |
| Sep 2023 | N/A | N/A | $3.74 | -$2.62 |
| Jun 2023 | N/A | N/A | $4.27 | -$3.32 |
| Mar 2023 | N/A | N/A | $6.84 | -$3.48 |
| Dec 2022 | N/A | N/A | $7.92 | -$3.76 |
| Sep 2022 | N/A | N/A | $9.61 | -$3.59 |
| Jun 2022 | N/A | N/A | $7.24 | -$2.97 |
| Mar 2022 | N/A | N/A | $12.91 | -$2.72 |
| Dec 2021 | N/A | N/A | $15.96 | -$3.81 |
| Sep 2021 | N/A | N/A | $16.07 | -$3.13 |
| Jun 2021 | N/A | N/A | $13.83 | -$2.25 |
CHRS average PE ratio chart
Currently, CHRS's PE ratio is under its 10-year average.
CHRS PE vs peers
CHRS's PE ratio is below its peer stocks AMGN and SRPT.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CHRS Coherus BioSciences Inc | 3.13 | $90.61M |
| SRPT Sarepta Therapeutics Inc | 22.04 | $5.28B |
| AMGN Amgen Inc | 38.63 | $158.15B |
| RGEN Repligen Corp | N/A | $6.29B |
| AGEN Agenus Inc | N/A | $39.48M |
Frequently asked questions
What is Coherus BioSciences's PE ratio?
The price to earnings ratio for CHRS stock as of Apr 4, 2025, stands at 3.13.
What is the highest PE ratio for CHRS?
The highest quarterly PE ratio in the last six years has been 13.96 and it was in the Dec 2019 quarter.
How does the current PE ratio for CHRS compare to its historical average?
CHRS's current price to earnings ratio is 64% below its 6-year historical average.
Why is Coherus BioSciences's PE ratio so low?
CHRS's PE ratio is low because its earnings per share (EPS) is high relative to its stock price.
How is CHRS's PE ratio calculated (Coherus BioSciences PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Apr 4, 2025), Coherus BioSciences's share price is $0.78. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $0.25. Therefore, Coherus BioSciences's price to earnings ratio for today is 3.13. PE RATIO(3.13) = STOCK PRICE($0.78) / TTM EPS($0.25)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.